Cyclophosphamide-induced bladder cancer in a patient with Wegener granuromatosis

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Cyclophosphamide (CPM) has been considered to be a factor of bladder carcinogen. A 60-years old woman had been received a total dose of 370 g of CPM for the treatment of Wegener's granulomatosis since August, 1977. She was consulted to our department with chief complaint of macrohematuria in August, 1986. Hemorrhage cystitis was diagnosed and cystoscopy and urine cytology were performed as follow-up schedule in every year. In 1996, urine cytology showed class IV and cystoscopy revealed multiple nonpapillary tumors. Abdominal computerized tomography demonstrated a low density mass on the posterior wall of the bladder. A transurethral cold cup biopsy showed G3 transitional cell carcinoma (TCC). Radical cystectomy and tubeless cutaneous ureterostomy was performed on December 6, 1996 and histopathological diagnosis was TCC, G3, pT3 bNXM 0. She died of liver failure due to metastatic bladder cancer after seven months postoperatively.

Cite

CITATION STYLE

APA

Shimizu, A., Ueda, T., Furuya, Y., Ichikawa, T., Akakura, K., Ito, H., … Isaka, S. (1999). Cyclophosphamide-induced bladder cancer in a patient with Wegener granuromatosis. Japanese Journal of Urology, 90(1), 53–56. https://doi.org/10.5980/jpnjurol1989.90.53

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free